Artificial Intelligence in Healthcare and Biotechnology Report 2026

As of 2025, healthcare and biotechnology have entered the most mature and most transformative phase of their digital shift. Artificial intelligence (AI) is no longer an experimental instrument or a supporting layer. It now sits at the operational center of every vertical process, from drug discovery to surgical operations, from genomic analysis to patient management. Chronic pressures on health systems worldwide, including staff shortages, rising costs and ageing populations, have turned AI integration from an option into a strategic necessity. The 2025 data confirms that the sector has moved past pilot projects into real world evidence and large-scale industrial deployment.1

What are the applications of artificial intelligence in healthcare?

Artificial intelligence in healthcare concentrates in four main application areas. Each one affects both clinical decision-making and operational efficiency directly:

• Disease diagnosis and treatment planning: Imaging data is analyzed to detect disease at an early stage, and personalized treatment plans are built around the patient’s genetic profile and clinical history.
• Robotic surgery: AI-powered systems enable less invasive, higher-precision operations and give the surgeon live decision support.
• Patient monitoring and care management: Wearables and remote monitoring systems track patient status continuously and raise an early warning when readings turn abnormal.
• Drug discovery and development: Large biological data sets are screened to identify new drug candidates, and potential side effects are predicted before the clinical stage.

Each of these four areas is examined in detail below with 2025 and 2026 data.

Global market dynamics and economic impact analysis

The global market for artificial intelligence in healthcare recorded exceptional growth momentum through 2024 and 2025. Market volume stood at 27.46 billion dollars in 2024 and reached 37.7 billion dollars in 2025. That growth rate points to a compound annual growth rate (CAGR) between 37.3% and 38.9% over the next decade (2026 to 2033), taking the market to somewhere between 476 billion and 505 billion dollars by 2033. Expansion on that scale signals that the technology has proven itself on both clinical and operational outcomes. The primary driver behind it is the expectation of higher operational efficiency and lower cost. Biotechnology and pharmaceutical companies stand out as the largest stakeholders, dominating more than 30% of the total market. Software solutions in particular have moved ahead of hardware and services with a 46% market share. Projections for 2025 suggest AI will create between 350 billion and 410 billion dollars in additional annual value in the pharmaceutical sector alone.5

Global healthcare AI market forecasts and segmentation

North America held 54% of the market in 2025 and kept its lead, backed by a well-established health system and intensive R&D activity. Europe, however, has become the fastest-growing region globally thanks to government digitalization drives, heavy investment in personalized medicine and ethical AI regulation. Countries including Germany and France moved their national strategies for medical imaging and patient data analysis to an operational level in 2025.2

Generative AI transformation in drug discovery and biotechnology

Drug development has historically been high cost, with investment reaching 2.6 billion dollars per programme, and low success, with rates below 10%.6 That development cycle, averaging 12 to 15 years, is the biggest efficiency bottleneck in biotechnology. 2025 marked the breaking point where the paradigm changed outright. The new generation of “AI-First” biotechnology companies is integrating AI five times faster than traditional firms.5

The algorithmic revolution in molecular design and protein engineering

Generative AI has become the core technology for unpacking the complexity of biological data. Projections indicate that 30% of new drug candidates will be discovered through AI methods as of 2025.5 The foundation models used in the process have evolved from systems such as AlphaFold3, which predicts protein structures from amino acid sequences, to models such as Genie, which design entirely new proteins that do not exist in nature.5 AlphaFold is currently in active use by more than 1.2 million researchers.5

Deep learning algorithms, particularly graph neural networks and transformer architectures, have reached accuracy as high as 94% in identifying molecular patterns associated with disease.6 These models screen millions of chemical compounds virtually, so only the candidates with the highest probability of success move to the laboratory stage. The approach carries the potential to compress discovery timelines from five or six years down to a single year.4

Core techniques and application areas in drug discovery

The most critical strategic shift of 2025 was the move from “data volume” to data maturity. Rather than simply collecting more data, companies now focus on making that data biologically coherent, high quality and standardized.1 That depth allows models to grasp causal relationships rather than stopping at correlation. Leading companies such as Insilico Medicine are making the entire target-to-drug process autonomous through platforms including Pharma.AI, announcing new molecules that reach the clinical stage within months.9

Optimizing clinical research and digital cell models

Clinical trials are the most expensive stage of health innovation and the one carrying the highest risk of failure. AI integration is reshaping the process both operationally and scientifically. AI-based solutions in clinical research are expected to represent a 7 billion dollar market as of 2025.5

Patient selection and TrialGPT platforms

The biggest obstacle in clinical trials is finding suitable patients and keeping them enrolled. Autonomous agents such as TrialGPT analyze electronic health records (EHR) within seconds to identify the best-matched participants, minimizing manual error in recruitment.5 The technology does more than add speed: it improves diversity in trials and predicts dropout in advance, preventing clinical interruptions. Janssen (Johnson & Johnson) integrating more than 100 AI projects into clinical trials through its Trials360.ai platform demonstrates the scale of the trend.5

Digital twins and alternatives to animal testing

Another transformative trend of 2025 is the digital cell model. These models simulate cell behavior by integrating multi-layered biological data, including omics data, imaging and perturbation experiments.1 Combined with the New Approach Methodologies (NAMs) backed by the FDA, the technology has started replacing animal testing across a wide field that runs from surgical planning to drug toxicity testing.1 The simulations target meaningful reductions in trial duration and savings of up to 25 billion dollars in development cost.5

New standards in smart surgery and robotic systems

Between 2024 and 2025, robotic surgery moved from being a simple visualization instrument to a semi-autonomous, decision-support system. AI-powered surgical robots no longer just transmit the surgeon’s movements; they provide real-time decision support during the operation.10 Companies including Intuitive Surgical, Medtronic and Johnson & Johnson MedTech have added AI layers to their robotic platforms, lifting surgical precision and patient safety to a new level.11

Clinical outcomes and operational efficiency analysis

A synthesis of 25 peer-reviewed studies from 2024 and 2025 demonstrates the clear advantages of AI-assisted robotic surgery over traditional methods. These systems raise the surgeon’s situational awareness and minimize fatigue-related error.10

Neuro-visual adaptive control and autonomy

The most important innovation raising the intelligence of surgical platforms in 2025 is neuro-visual adaptive control. The technology builds a feedback loop that monitors the surgical field continuously, adjusting the robot’s movements in real time and minimizing unwanted motion that could harm the patient.10 Large vision models (LVM) have also gained the ability to interpret complex surgical fields and identify critical anatomical structures automatically.10 That opens the door to AI performing specific procedures such as autonomous suturing.

Diagnostic imaging and multimodal artificial intelligence

Medical imaging is one of the areas where AI integrated earliest and most successfully. By 2025, AI use in radiology and pathology workflows had shifted from optional feature to baseline standard. Companies such as GE HealthCare and Siemens Healthineers have pushed diagnostic accuracy to its peak with AI-powered MRI and CT scanners.3

The multimodal approach: a symphony of data

Traditional AI models focus on a single data type, an X-ray image for example, whereas the rising trend of 2025 is multimodal AI. These systems analyze radiological images, genomic data, pathology slides and the patient’s clinical history simultaneously.12 Giants including Bayer and Philips use multimodal architectures to generate synthetic images for diagnosing rare diseases, closing the gap left by missing training data.12

The breaking point in diagnostic accuracy and accessibility

AI systems have a clear edge in detecting the micro patterns a human radiologist can miss. Systems reaching high accuracy in detecting lung nodules, for instance, affect cancer survival rates directly through earlier diagnosis.7 AI-powered chest X-ray systems rolled out across 17 separate facilities in regions such as India process 2,000 scans a day, closing health gaps where specialist physicians are scarce.7 As of 2025, digital health solutions are expected to compress the time from diagnosis to billing by 50%.2

Real-world applications and case studies

Field deployments show what the market data above means clinically.

AI-powered imaging (NHS): The UK National Health Service (NHS) cut screening time by roughly 30% and improved diagnostic accuracy with the AI-powered imaging system it uses for lung cancer diagnosis. The system pre-assesses scans with deep learning algorithms and flags the suspicious areas the physician needs to review.

Sepsis early warning system (Johns Hopkins): Johns Hopkins Hospital detects the early signs of sepsis with an AI system that analyzes vital signs, laboratory results and electronic health records together. Earlier identification shortens time to treatment and has raised survival rates.

Both examples show that the clinical value of artificial intelligence comes not from algorithm performance alone but from integration into the existing workflow.

Turkey’s national artificial intelligence strategy and health vision

Under the 2021 to 2025 National Artificial Intelligence Strategy and the 2024 to 2025 action plan, Turkey has placed artificial intelligence at the center of national development and digital transformation in healthcare.13 Updated by the Presidency’s Digital Transformation Office and the Ministry of Industry and Technology, these documents reinforce Turkey’s ambition to be a technology exporter in the field rather than only a user.13

TUSEB and TUYZE: a strategic bridge from academia to the clinic

The Turkish Institute of Health Data Research and Artificial Intelligence Applications (TUYZE), operating under the Health Institutes of Turkey (TUSEB), plays a critical role in the 2025 projections. The “From Data to Decision: National Artificial Intelligence Summit” held in 2025, along with a series of workshops, has helped shape public policy on an evidence base.15

Domestic success stories and the investment ecosystem

2024 and 2025 were the years Turkish health technology ventures earned global recognition. SmartAlpha, based at METU Technopark, became the first domestic company to receive clinical use approval from the US Food and Drug Administration (FDA) for its artificial intelligence software.18 The achievement demonstrates the capacity of Turkish engineering to meet global regulation. Ventures such as PhiTech Bioinformatics are also continuing to grow in genomic data analysis and personalized medicine, backed by investment from institutions including Eksim Ventures.18

Turkey venture ecosystem investment data (Q3 2025)

In the first nine months of 2025, ventures in Turkey raised a total of 475 million dollars. AI-based ventures accounted for 17.7% of all deals over the past five years, proving they are the most dynamic part of the ecosystem.20

Data privacy, ethics and the regulatory framework in 2025

As artificial intelligence spreads through healthcare, it brings serious ethical and legal responsibility with it. 2025 was the year regulation in this field moved from advisory to legally binding. Protecting patient data and keeping algorithms transparent are the foundations of trust.23

The EU AI Act and legislative work in Turkey

The European Union Artificial Intelligence Act (AI Act), in force since 1 August 2024, classifies health applications as high risk and imposes strict oversight and risk management obligations.14 Turkey does not yet have a standalone AI law, but the “Generative Artificial Intelligence and the Protection of Personal Data Guide” published by the Personal Data Protection Authority (KVKK) on 24 November 2025 offers the sector a critical roadmap.26 The guide provides the first official definitions of concepts including deep learning and deep fake.26

Critical ethical problems and how they are being solved

The core ethical obstacles in AI development also determine how readily society accepts the technology:

• Algorithmic bias: Models trained on unrepresentative data sets risk producing incorrect diagnoses for specific populations. Inclusive data collection and continuous monitoring became mandatory strategies for addressing this in 2025.24
• Explainable AI: Rather than black-box models, transparent models that show which data a decision was based on are what earn physician trust.24
• Responsibility and accountability: The question of who is liable when AI errs is answered by the human-in-the-loop principle, where the final decision always belongs to the physician.27
• Data minimization and encryption: For KVKK and GDPR compliance, anonymizing data, encrypting it end to end and using it only for the stated purpose (purpose-based consent) are baseline requirements.23

Operational efficiency and workforce transformation

The healthcare workforce gap is a crisis expected to reach 11 million workers worldwide by 2030.3 Artificial intelligence has become the most important instrument for managing it. The automation the technology provides reduces the administrative load on health workers and lets them focus on the patient.

Agentic AI and administrative automation

Administrative tasks that consume a large share of clinical time, including medical coding, billing, appointment scheduling and discharge reporting, are now being handled autonomously by agentic AI systems.7 These will be one of the fastest-growing sub-segments between 2025 and 2030 with growth of 35% to 40%.7 Ventures such as Kairoi and Wellora minimize documentation time with the AI assistants they build for clinicians.7

Site-of-care shifts

Artificial intelligence and remote monitoring are pushing care out of hospitals and into community settings and homes. As of 2025, more than 30% of major joint operations take place in ambulatory surgery centers (ASC), and that share is expected to reach 60% by 2027.30 The shift matches patient preference while delivering cost savings of up to 40% for health systems.30 Real-time data collected through smartwatches and wearables has accelerated preventive care and cut hospital admissions by 30%.2

Biosecurity and smart biosensors

Another critical front for AI in healthcare is the fight against antimicrobial resistance (AMR) and global disease surveillance. AI-powered optical and electrochemical biosensors enable point-of-care detection, reducing dependence on the laboratory.32

AMR surveillance and outbreak prediction

AI models analyze vast data sets from hospitals, laboratories and environmental sensors, and can detect outbreaks before official announcements.34 NATO beginning to fund AI-focused biotechnology firms against biosecurity threats in June 2025 shows the strategic weight of the technology.34 Powered by machine learning algorithms, smart biosensors provide real-time decision support across a wide range that runs from food safety to pathogen detection.33

Future projection: 2026 and beyond

Strategic projections for 2026 point to full integration of artificial intelligence with biology. The sector is no longer just using models; it is positioning them as infrastructure, or AI-as-Infrastructure. According to Deloitte’s 2026 Life Sciences Outlook report, 41% of sector leaders see generative artificial intelligence as the most influential trend.1

Leading future trends and strategic priorities

• Sovereign AI: Countries developing national, secure health models on their own health data will become a primary priority for data sovereignty and national security.36
• Green AI: Carbon-neutral data centers and low-energy chips that reduce the power consumption of large language models and biological simulations are part of the 2026 vision.37
• From digital twins to personalized medicine: As AI processes each patient’s genetic profile, protein expression and lifestyle data, one-size-fits-all treatment will give way to fully personalized protocols.34 Caris Life Sciences profiling 849,000 cancer cases with AI is a concrete example of that future.34

Sector conclusion and strategic recommendations

AI integration in healthcare and biotechnology reached a point of no return in 2025. This technological shift is not an update to medical devices or software; it is a fundamental redesign of how health services are delivered. The 2025 data proves beyond doubt that AI compresses drug discovery timelines dramatically, reduces surgical complications and raises administrative efficiency.

For organizations, success will not come from buying the most advanced models. It will come from building the high-quality data infrastructure that feeds them, complying with ethical standards and global regulation (AI Act, KVKK), and integrating human-machine collaboration into operational culture. In Turkey specifically, publicly backed projects such as TUYZE and domestic success stories such as FDA-approved SmartAlpha have the potential to make the country a strategic player in the global health technology market. Sector stakeholders that build their 2026 vision around data quality, explainable AI and sustainability will be the ones who maximize what this dynamic market offers. To measure your brand’s visibility in AI search, review our Generative Engine Optimization (GEO) service.

Works cited

1. AI in Biotech: Lessons from 2025 and the Trends Shaping Drug …, accessed February 4, 2026, https://ardigen.com/ai-in-biotech-lessons-from-2025-and-the-trends-shaping-drug-discovery-in-2026/
2. AI in Healthcare Market Size, Key Players | Report [2033] - SkyQuest …, accessed February 4, 2026, https://www.skyquestt.com/report/artificial-intelligence-ai-in-healthcare-market
3. The Future of Medicine: 6 Ways AI is Transforming Healthcare in 2025 - Launch Consulting, accessed February 4, 2026, https://www.launchconsulting.com/posts/the-future-of-medicine-6-ways-ai-is-transforming-healthcare-in-2025
4. AI In Healthcare Market Size & Share | Industry Report, 2033 - Grand View Research, accessed February 4, 2026, https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-ai-healthcare-market
5. AI in Pharma and Biotech: Market Trends 2025 and Beyond, accessed February 4, 2026, https://www.coherentsolutions.com/insights/artificial-intelligence-in-pharmaceuticals-and-biotechnology-current-trends-and-innovations
6. A New Era of Artificial Intelligence (AI): Transforming Drug Discovery and Development | Journal of Medicinal Chemistry - ACS Publications, accessed February 4, 2026, https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c03159
7. Top 10 AI Trends in Healthcare [2025] | StartUs Insights, accessed February 4, 2026, https://www.startus-insights.com/innovators-guide/emerging-ai-trends-in-healthcare/
8. AI in Drug Discovery: 2025 Trends, Tools & Use Cases - Ideas2IT, accessed February 4, 2026, https://www.ideas2it.com/blogs/ai-in-drug-discovery
9. Insilico Medicine: Main, accessed February 4, 2026, https://insilico.com/
10. The rise of robotics and AI-assisted surgery in modern healthcare …, accessed February 4, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12181090/
11. Top 20 Medtech Companies Leveraging AI in 2025 | IntuitionLabs, accessed February 4, 2026, https://intuitionlabs.ai/articles/top-20-medtech-companies-using-ai-2025
12. How GenAI will transform life sciences in 2025 - pharmaphorum, accessed February 4, 2026, https://pharmaphorum.com/digital/how-genai-will-transform-life-sciences-2025
13. Ulusal Yapay Zeka Stratejisi 2024-2025 Eylem Plani - ODMD, accessed February 4, 2026, https://www.odmd.org.tr/web_2837_1/entitialfocus.aspx?primary_id=4749&type=31&target=categorial1&detail=single&sp_table=&sp_primary=&sp_table_extra=
14. Data protection and privacy law in Turkey: key developments and outlook, accessed February 4, 2026, https://gun.av.tr/media/rernzgat/fikir-liderligi-kvkk-2025.pdf
15. TUSEB’s digital health vision shared at ITU - Turkish Institute of Health Data Research and Artificial Intelligence Applications, accessed February 4, 2026, https://tuyze.tuseb.gov.tr/haberler/tusebin-dijital-saglik-vizyonu-itude-paylasildi-20250808
16. Turkish Institute of Health Data Research and Artificial Intelligence Applications - TUSEB, accessed February 4, 2026, https://tuyze.tuseb.gov.tr/tr/haberler/p/3
17. Turkish Institute of Health Data Research and Artificial Intelligence Applications, accessed February 4, 2026, https://tuyze.tuseb.gov.tr/
18. SmartAlpha, founded at METU Technopark, becomes the first domestic AI company to receive FDA approval in the US - egirisim, accessed February 4, 2026, https://egirisim.com/2025/08/20/odtu-teknokentte-kurulan-smartalpha-amerikada-fda-onayi-alan-ilk-yerli-yapay-zeka-sirketi-oldu/
19. Recently Funded Startups in Turkiye (Nov-2025) - FundedIQ, accessed February 4, 2026, https://fundediq.co/funded-startups-turkey/
20. Turkish Startup Investments Review Q3 2025 - KPMG agentic corporate services, accessed February 4, 2026, https://assets.kpmg.com/content/dam/kpmg/tr/pdf/2025/11/turkish-startup-investments-q3-20252.pdf
21. Turkish Startup Investments Review 2024 - KPMG agentic corporate services, accessed February 4, 2026, https://assets.kpmg.com/content/dam/kpmg/tr/pdf/2025/02/Turkish Startup Investments Review Q4 2024.pdf
22. Turkish startups attract $475 million in first nine months of 2025 - Hurriyet Daily News, accessed February 4, 2026, https://www.hurriyetdailynews.com/turkish-startups-attract-475-million-in-first-nine-months-of-2025-214732
23. Data Privacy & AI Ethics Best Practices | Governance Guidance 2025 - TrustCommunity, accessed February 4, 2026, https://community.trustcloud.ai/docs/grc-launchpad/grc-101/governance/data-privacy-and-ai-ethical-considerations-and-best-practices/
24. Ethics of AI in Healthcare: Navigating Privacy, Bias, and Trust in 2025 - Alation, accessed February 4, 2026, https://www.alation.com/blog/ethics-of-ai-in-healthcare-privacy-bias-trust-2025/
25. AI Ethics in Healthcare: Challenges, Regulations, and Solutions - Daiki, accessed February 4, 2026, https://dai.ki/blog/ai-ethics-in-healthcare-challenges-regulations-and-solutions/
26. Guide on generative artificial intelligence and the protection of personal data published - Herguner, accessed February 4, 2026, https://herguner.av.tr/yapay-zeka/
27. Guide to the responsible and trustworthy use of generative artificial intelligence in support processes - TUBITAK, accessed February 4, 2026, https://tubitak.gov.tr/sites/default/files/2025-09/uyz_rehberi_ardeb.pdf
28. Legal regulation of artificial intelligence applications in healthcare: current and expected legislation - Mahmut Adnan Akyuz, accessed February 4, 2026, https://mahmutakyuz.com/saglikta-yapay-zeka-uygulamalarinin-yasal-duzenlemeleri-yapay-zekanin-saglikta-kullanimina-yonelik-mevcut-ve-beklenen-yasal-duzenlemeler/
29. Consent Management Challenges in Healthcare Data Sharing 2025 - Secure Privacy, accessed February 4, 2026, https://secureprivacy.ai/blog/healthcare-data-sharing-challenges-2025
30. Medtech Trends 2025: AI, robotics and future healthcare shifts | ZS, accessed February 4, 2026, https://www.zs.com/insights/medtech-trends-2025-healthcare-innovation
31. AI in health and care: key legal risks to navigate in managing data privacy | Gowling WLG, accessed February 4, 2026, https://gowlingwlg.com/en/insights-resources/articles/2025/ai-in-health-and-care-key-legal-risks-to-navigate-in-managing-data-privacy
32. Emerging trends in AI-integrated optical biosensors for point-of-care diagnostics: current status and future prospects - RSC Publishing, accessed February 4, 2026, https://pubs.rsc.org/en/content/articlehtml/2025/cc/d5cc04899k
33. Artificial Intelligence-Integrated Biosensors for Antimicrobial Resistance Detection and Surveillance: A Review and Future Perspectives for Global Biosecurity - PMC, accessed February 4, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12750469/
34. How AI Will Impact the Biotech Industry In 2025, accessed February 4, 2026, https://biotechbreakthroughawards.com/how-ai-will-impact-the-biotech-industry-in-2025/
35. Integration of Artificial Intelligence in Biosensors for Enhanced Detection of Foodborne Pathogens - MDPI, accessed February 4, 2026, https://www.mdpi.com/2079-6374/15/10/690
36. Artificial Intelligence Integration in the Manufacturing Sector, Webtures Insights, accessed February 4, 2026
37. 2025 Technology Trends - OGGUSTO, accessed February 4, 2026, https://www.oggusto.com/teknoloji/2025-teknoloji-trendleri